SENP7

Summary

SENP7 (SUMO specific peptidase 7, HGNC:30402) is a protein-coding gene on chromosome 3q12.3, encoding Sentrin-specific protease 7 (Q9BQF6). Protease that acts as a positive regulator of the cGAS-STING pathway by catalyzing desumoylation of CGAS.

The reversible posttranslational modification of proteins by the addition of small ubiquitin-like SUMO proteins (see SUMO1; MIM 601912) is required for many cellular processes. SUMO-specific proteases, such as SENP7, process SUMO precursors to generate a C-terminal diglycine motif required for the conjugation reaction. They also display isopeptidase activity for deconjugation of SUMO-conjugated substrates (Lima and Reverter, 2008 [PubMed 18799455]).

Source: NCBI Gene 57337 — RefSeq curated summary.

At a glance

• Gene–disease (curated): arthrogryposis multiplex congenita (Strong, GenCC)
• GWAS associations: 16
• Clinical variants (ClinVar): 137 total — 1 pathogenic, 2 likely-pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_020654

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30402
Approved symbol	SENP7
Name	SUMO specific peptidase 7
Location	3q12.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000138468
Ensembl biotype	protein_coding
OMIM	612846
Entrez	57337

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 retained_intron

ENST00000314261, ENST00000348610, ENST00000366089, ENST00000394085, ENST00000394091, ENST00000394094, ENST00000394095, ENST00000460107, ENST00000958688, ENST00000958689

RefSeq mRNA: 5 — MANE Select: NM_020654 NM_001077203, NM_001282801, NM_001282802, NM_001282803, NM_020654

CCDS: CCDS2941, CCDS43121, CCDS63704, CCDS63705, CCDS63706

Canonical transcript exons

ENST00000394095 — 24 exons

Exon	Start	End
ENSE00000934102	101327666	101327816
ENSE00000934103	101328478	101328546
ENSE00000934104	101328646	101328689
ENSE00000934105	101330334	101330386
ENSE00000934106	101331985	101332109
ENSE00000967262	101398861	101399055
ENSE00000967263	101372008	101372126
ENSE00000967264	101367830	101368011
ENSE00000967265	101366430	101366769
ENSE00000967266	101364834	101364991
ENSE00000967267	101361715	101361861
ENSE00000967269	101343686	101343954
ENSE00000967270	101341646	101341779
ENSE00000967271	101340095	101340211
ENSE00000967272	101337509	101337631
ENSE00000967273	101332770	101332862
ENSE00001014442	101351618	101351651
ENSE00001209748	101458955	101459052
ENSE00001252388	101347872	101348051
ENSE00001386624	101417593	101417790
ENSE00001866860	101324205	101326080
ENSE00003493796	101513091	101513212
ENSE00003560172	101501070	101501119
ENSE00003668679	101493873	101493968

Expression profiles

Bgee: expression breadth ubiquitous, 261 present calls, max score 95.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.4218 / max 229.6578, expressed in 1693 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43545	10.7162	1656
43544	1.3899	679
43543	0.3158	165

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	95.15	gold quality
adrenal tissue	UBERON:0018303	91.87	gold quality
left ovary	UBERON:0002119	91.81	gold quality
right ovary	UBERON:0002118	91.60	gold quality
ganglionic eminence	UBERON:0004023	91.22	gold quality
ventricular zone	UBERON:0003053	91.00	gold quality
tibia	UBERON:0000979	90.82	gold quality
body of uterus	UBERON:0009853	90.55	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.46	gold quality
right uterine tube	UBERON:0001302	90.43	gold quality
mucosa of stomach	UBERON:0001199	90.38	gold quality
tibial nerve	UBERON:0001323	90.27	gold quality
endothelial cell	CL:0000115	90.25	gold quality
left uterine tube	UBERON:0001303	90.02	gold quality
cortical plate	UBERON:0005343	89.76	gold quality
ovary	UBERON:0000992	89.75	gold quality
endometrium	UBERON:0001295	89.68	gold quality
body of pancreas	UBERON:0001150	89.48	gold quality
mucosa of paranasal sinus	UBERON:0005030	89.20	gold quality
endocervix	UBERON:0000458	88.60	gold quality
corpus callosum	UBERON:0002336	88.50	gold quality
germinal epithelium of ovary	UBERON:0001304	88.28	gold quality
sural nerve	UBERON:0015488	88.08	gold quality
descending thoracic aorta	UBERON:0002345	87.91	gold quality
lymph node	UBERON:0000029	87.89	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.59	gold quality
monocyte	CL:0000576	87.57	gold quality
tendon	UBERON:0000043	87.30	gold quality
ectocervix	UBERON:0012249	87.25	gold quality
subcutaneous adipose tissue	UBERON:0002190	87.14	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

83 targeting SENP7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-545-3P	99.95	70.74	2783
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-338-5P	99.92	72.34	2951

Literature-anchored findings (GeneRIF, showing 9)

• SENP6 and SENP7 exhibit lower rates for processing pre-SUMO1, pre-SUMO2, or pre-SUMO3 in comparison with SENP2 (PMID:18799455)
• Loop 1 insertion in SENP6 and SENP7 as a platform to discriminate between SUMO1 and SUMO2/3 isoforms in this subclass of the SUMO protease family. (PMID:21878624)
• differential splicing of the SENP7 regulates either tumor suppression or progression (PMID:23045645)
• deSUMOylation by SENP7 is required to promote a permissive chromatin environment for DNA repair. (PMID:24018422)
• c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4 (PMID:25895136)
• non-tumorigenic MCF10-2A cells with reduced SENP7S exhibit greater cell proliferation and anchorage-dependent growth. SENP7S depletion directly potentiates tumorigenic properties of MCF10-2A cells with induction of anchorage-independent growth and self-renewal in 3D-spheroid conditions. Collectively, the results identify SENP7S as a novel mediator of beta-catenin signaling and normal mammary epithelial cell physiology. (PMID:28429743)
• SPOP inhibits hepatocellular carcinoma (HCC) cell metastasis via ubiquitin-dependent SENP7 proteolysis and may thus serve as a new opinion for the prevention of HCC metastasis. (PMID:29777712)
• DeSUMOylase SENP7-Mediated Epithelial Signaling Triggers Intestinal Inflammation via Expansion of Gamma-Delta T Cells. (PMID:31825833)
• SENP7 senses oxidative stress to sustain metabolic fitness and antitumor functions of CD8+ T cells. (PMID:35143421)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	senp7b	ENSDARG00000061138
danio_rerio	si:dkey-100n23.3	ENSDARG00000062148
mus_musculus	Senp7	ENSMUSG00000052917
drosophila_melanogaster	pira	FBGN0030420
caenorhabditis_elegans		WBGENE00006739

Paralogs (1): SENP6 (ENSG00000112701)

Protein

Protein identifiers

Sentrin-specific protease 7 — Q9BQF6 (reviewed: Q9BQF6)

Alternative names: SUMO-1-specific protease 2, Sentrin/SUMO-specific protease SENP7

All UniProt accessions (3): Q9BQF6, H7C1X8, J3QT09

UniProt curated annotations — full annotation on UniProt →

Function. Protease that acts as a positive regulator of the cGAS-STING pathway by catalyzing desumoylation of CGAS. Desumoylation of CGAS promotes DNA-binding activity of CGAS, subsequent oligomerization and activation. Deconjugates SUMO2 and SUMO3 from targeted proteins, but not SUMO1. Catalyzes the deconjugation of poly-SUMO2 and poly-SUMO3 chains. Has very low efficiency in processing full-length SUMO proteins to their mature forms.

Subcellular location. Cytoplasm.

Similarity. Belongs to the peptidase C48 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9BQF6-1	1	yes
Q9BQF6-2	2
Q9BQF6-3	3
Q9BQF6-4	4
Q9BQF6-5	5

RefSeq proteins (5): NP_001070671, NP_001269730, NP_001269731, NP_001269732, NP_065705* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003653	Peptidase_C48_C	Domain
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily
IPR051947	Sentrin-specific_protease	Family

Pfam: PF02902

Enzyme classification (BRENDA):

• EC 3.4.22.B75 — (BRENDA: organisms, substrates, inhibitors, Km, kcat entries)

UniProt features (62 total): helix 12, strand 9, modified residue 8, compositionally biased region 7, sequence conflict 7, region of interest 5, splice variant 5, active site 3, sequence variant 2, mutagenesis site 2, chain 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7R2E	X-RAY DIFFRACTION	1.74
3EAY	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BQF6-F1	57.05	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 860; 939; 992 (nucleophile)

Post-translational modifications (8): 11, 12, 13, 25, 373, 433, 443, 444

Mutagenesis-validated functional residues (2):

Position	Phenotype
775	slightly increased deconjugation activity.
779	reduces deconjugation activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 143 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_UP, TGCGCANK_UNKNOWN, ATGCAGT_MIR217, GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_REMOVAL, GOBP_PEPTIDYL_LYSINE_MODIFICATION, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOMF_CYSTEINE_TYPE_PEPTIDASE_ACTIVITY, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_DEFENSE_RESPONSE_TO_VIRUS, NOUZOVA_TRETINOIN_AND_H4_ACETYLATION, GOBP_RESPONSE_TO_VIRUS, GOCC_POSTSYNAPSE, GOCC_SYNAPSE, LEE_RECENT_THYMIC_EMIGRANT, GOBP_PROTEOLYSIS

GO Biological Process (5): proteolysis (GO:0006508), protein desumoylation (GO:0016926), antiviral innate immune response (GO:0140374), immune system process (GO:0002376), innate immune response (GO:0045087)

GO Molecular Function (5): SUMO-specific endopeptidase activity (GO:0070139), protein binding (GO:0005515), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), presynaptic cytosol (GO:0099523), postsynaptic cytosol (GO:0099524)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytosol	2
protein metabolic process	1
peptidyl-lysine modification	1
protein modification by small protein removal	1
innate immune response	1
defense response to virus	1
biological_process	1
immune response	1
defense response to symbiont	1
ubiquitin-like protein-specific endopeptidase activity	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
presynapse	1
postsynapse	1

Protein interactions and networks

STRING

1566 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SENP7	SUMO2	P55855	902
SENP7	RANGAP1	P46060	900
SENP7	SUMO1	P55856	890
SENP7	UBE2I	P50550	678
SENP7	SAE1	Q9UBE0	673
SENP7	RAP2A	P10114	657
SENP7	SENP8	Q96LD8	651
SENP7	DESI1	Q6ICB0	645
SENP7	CBX5	P45973	631
SENP7	RAP1A	P10113	617
SENP7	UBA2	Q9UBT2	605
SENP7	USPL1	Q5W0Q7	604
SENP7	RNF4	P78317	579
SENP7	DESI2	Q9BSY9	578
SENP7	PIAS4	Q8N2W9	571

IntAct

22 interactions, top by confidence:

A	B	Type	Score
CBX5	SENP7	psi-mi:“MI:0915”(physical association)	0.670
SENP7	TRIM28	psi-mi:“MI:0915”(physical association)	0.560
DAXX	TNRC18	psi-mi:“MI:0914”(association)	0.530
SENP7	VIM	psi-mi:“MI:0915”(physical association)	0.400
P		psi-mi:“MI:0914”(association)	0.350
CBX5	ZNF568	psi-mi:“MI:0914”(association)	0.350
H2BC21	SMCHD1	psi-mi:“MI:0914”(association)	0.350
ZCCHC10	C1orf226	psi-mi:“MI:0914”(association)	0.350
DAXX	SETD1A	psi-mi:“MI:0914”(association)	0.350
SETDB2	DHX16	psi-mi:“MI:0914”(association)	0.350
CBX3	ZNF324	psi-mi:“MI:0914”(association)	0.350
DAXX		psi-mi:“MI:0914”(association)	0.350
BCL6	CACNA1A	psi-mi:“MI:0914”(association)	0.350
CBX3	MYL12B	psi-mi:“MI:0914”(association)	0.350
CBX5	ZNF292	psi-mi:“MI:0914”(association)	0.350
SENP7	MYL12B	psi-mi:“MI:0914”(association)	0.350
HNRNPC	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
RBM15	ILVBL	psi-mi:“MI:2364”(proximity)	0.270
ZRANB2	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
NPM1	SBNO1	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (41): SENP7 (Synthetic Lethality), SENP7 (Affinity Capture-MS), SENP7 (Affinity Capture-MS), SENP7 (Affinity Capture-MS), CSTA (Affinity Capture-MS), MYL12B (Affinity Capture-MS), RBBP4 (Affinity Capture-MS), TRIM28 (Affinity Capture-MS), AHDC1 (Affinity Capture-MS), CBX3 (Affinity Capture-MS), CBX5 (Affinity Capture-MS), CHAMP1 (Affinity Capture-MS), SENP7 (Affinity Capture-Western), SPOP (Affinity Capture-Western), SENP7 (Affinity Capture-RNA)

ESM2 similar proteins: A0JM80, A6H8Y1, A7MBJ2, D3ZF42, E9Q6J5, F4I700, F4J3S1, F4KCE9, F6QRE9, O04251, O82345, P23497, P46100, P48785, P48786, Q04996, Q05B65, Q0WTB8, Q13342, Q15361, Q32MZ4, Q3UZ39, Q3ZBR9, Q4QSC8, Q571C7, Q5H9K5, Q5RHP9, Q61687, Q66HF9, Q7YQM3, Q7YQM4, Q7Z5L2, Q8BJM3, Q8C4A5, Q8C9B9, Q8GZ87, Q8H991, Q8IW19, Q92576, Q940Y3

Diamond homologs: A7MBJ2, D3ZF42, O13769, O42957, Q02724, Q6P7W0, Q8BUH8, Q8GYL3, Q8L7S0, Q94F30, Q9BQF6, Q9GZR1, Q0WKV8, Q2PS26, Q8RWN0, O65278, P59110, Q09353, Q5R7K7, Q5RBB1, Q6NXL6, Q8WP32, Q91ZX6, Q96HI0, Q9EP97, Q9EQE1, Q9H4L4, Q9HC62, Q9P0U3, O13612, Q09275, Q23238

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

137 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	98
Likely benign	12
Benign	5

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
4072000	NM_020654.5(SENP7):c.973C>T (p.Gln325Ter)	Pathogenic
2501008	NM_020654.5(SENP7):c.1474C>T (p.Gln492Ter)	Likely pathogenic
3340479	NM_020654.5(SENP7):c.3088C>T (p.Arg1030Trp)	Likely pathogenic

SpliceAI

5067 predictions. Top by Δscore:

Variant	Effect	Δscore
3:101326078:ATCC:A	acceptor_loss	1.0000
3:101326079:TC:T	acceptor_gain	1.0000
3:101326079:TCCT:T	acceptor_loss	1.0000
3:101326080:CC:C	acceptor_gain	1.0000
3:101328473:CT:C	donor_loss	1.0000
3:101328473:CTTA:C	donor_gain	1.0000
3:101328474:TT:T	donor_loss	1.0000
3:101328475:TACT:T	donor_loss	1.0000
3:101328476:A:AC	donor_gain	1.0000
3:101328476:AC:A	donor_loss	1.0000
3:101328476:ACT:A	donor_gain	1.0000
3:101328476:ACTCT:A	donor_gain	1.0000
3:101328477:C:CA	donor_gain	1.0000
3:101328477:CT:C	donor_gain	1.0000
3:101328477:CTC:C	donor_gain	1.0000
3:101328477:CTCT:C	donor_gain	1.0000
3:101328477:CTCTC:C	donor_gain	1.0000
3:101328543:TGGC:T	acceptor_gain	1.0000
3:101328545:GCCTA:G	acceptor_loss	1.0000
3:101328546:CC:C	acceptor_loss	1.0000
3:101328546:CCTA:C	acceptor_gain	1.0000
3:101328547:C:CC	acceptor_gain	1.0000
3:101328548:T:C	acceptor_loss	1.0000
3:101328549:A:AC	acceptor_gain	1.0000
3:101328549:A:C	acceptor_gain	1.0000
3:101328641:CCTA:C	donor_loss	1.0000
3:101328644:ACC:A	donor_loss	1.0000
3:101328686:TACTC:T	acceptor_loss	1.0000
3:101328687:ACTCT:A	acceptor_loss	1.0000
3:101328688:CT:C	acceptor_gain	1.0000

AlphaMissense

6919 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:101326033:A:C	F1021L	1.000
3:101326033:A:T	F1021L	1.000
3:101326034:A:G	F1021S	1.000
3:101326035:A:G	F1021L	1.000
3:101326038:A:G	W1020R	1.000
3:101326038:A:T	W1020R	1.000
3:101327691:A:G	L997S	1.000
3:101327703:C:T	G993E	1.000
3:101327704:C:G	G993R	1.000
3:101327704:C:T	G993R	1.000
3:101327705:A:C	C992W	1.000
3:101327706:C:T	C992Y	1.000
3:101327707:A:G	C992R	1.000
3:101327723:C:A	Q986H	1.000
3:101327723:C:G	Q986H	1.000
3:101327733:A:T	V983D	1.000
3:101328481:C:G	R954P	1.000
3:101328526:T:A	D939V	1.000
3:101328535:A:G	L936P	1.000
3:101332089:A:T	V865D	1.000
3:101332100:C:A	W861C	1.000
3:101332100:C:G	W861C	1.000
3:101332102:A:G	W861R	1.000
3:101332102:A:T	W861R	1.000
3:101332105:G:C	H860D	1.000
3:101332826:C:A	W839C	1.000
3:101332826:C:G	W839C	1.000
3:101332828:A:G	W839R	1.000
3:101332828:A:T	W839R	1.000
3:101337574:A:C	S805R	1.000

dbSNP variants (sampled 300 via entrez): RS1000000241 (3:101476277 G>A), RS1000000322 (3:101387696 C>A,T), RS1000009165 (3:101432613 G>A), RS1000015585 (3:101339004 T>G), RS1000024397 (3:101513342 T>C), RS1000040786 (3:101395145 C>G), RS1000053372 (3:101374534 T>C), RS1000100321 (3:101483368 C>T), RS1000158959 (3:101495305 T>C), RS1000179356 (3:101438868 C>T), RS1000182907 (3:101473534 T>C), RS1000194688 (3:101346248 A>G), RS1000196503 (3:101395287 G>A), RS1000212696 (3:101452591 C>G), RS1000234625 (3:101445983 A>G)

Disease associations

OMIM: gene MIM:612846 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
arthrogryposis multiplex congenita	Strong	Autosomal recessive

Mondo (1): arthrogryposis multiplex congenita (MONDO:0015168)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST004131_6	Inflammatory bowel disease	3.000000e-08
GCST004132_78	Crohn’s disease	4.000000e-07
GCST004630_120	Mean corpuscular hemoglobin	2.000000e-09
GCST007268_71	Diastolic blood pressure	9.000000e-13
GCST007511_24	Alzheimer’s disease (late onset)	4.000000e-06
GCST008522_94	Bitter alcoholic beverage consumption	8.000000e-06
GCST009066_33	Mosaic loss of chromosome Y (Y chromosome dosage)	8.000000e-19
GCST009067_24	Mosaic loss of chromosome Y (Y chromosome dosage)	6.000000e-44
GCST009856_15	Leukocyte telomere length	2.000000e-08
GCST010043_112	Asthma	4.000000e-08
GCST90002400_365	Plateletcrit	2.000000e-12
GCST90002403_548	Red blood cell count	5.000000e-13
GCST90011900_21	Serum alkaline phosphatase levels	2.000000e-10
GCST90013406_240	Liver enzyme levels (alkaline phosphatase)	2.000000e-20
GCST90020025_585	Waist-to-hip ratio adjusted for BMI	1.000000e-08
GCST90020027_362	Waist-hip index	5.000000e-09

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0006336	diastolic blood pressure
EFO:1001870	late-onset Alzheimers disease
EFO:0010092	bitter alcoholic beverage consumption measurement
EFO:0007783	mosaic loss of chromosome Y measurement
EFO:0007985	platelet crit
EFO:0004305	erythrocyte count
EFO:0004533	alkaline phosphatase measurement
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1741213 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 5,477 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL165790	IPRIFLAVONE	2	5,477

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — C48: Ulp1 endopeptidase

Binding affinities (BindingDB)

8 measured of 18 human assays (18 total across all organisms); most potent 8 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
SPI-02	IC50	2100 nM	US-9791447: Methods of identifying SENP1 inhibitors
SPI-04	IC50	2400 nM	US-9791447: Methods of identifying SENP1 inhibitors
SPI-10	IC50	2400 nM	US-9791447: Methods of identifying SENP1 inhibitors
NSC8676	IC50	3800 nM	US-9791447: Methods of identifying SENP1 inhibitors
NSC70551	IC50	3900 nM	US-9791447: Methods of identifying SENP1 inhibitors
SPI-01	IC50	5900 nM	US-9791447: Methods of identifying SENP1 inhibitors
SPI-05	IC50	13300 nM	US-9791447: Methods of identifying SENP1 inhibitors
SPI-08	IC50	22200 nM	US-9791447: Methods of identifying SENP1 inhibitors

ChEMBL bioactivities

670 potent at pChembl≥5 of 900 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.45	IC50	359	nM	CHEMBL3196451
6.31	IC50	490	nM	CHEMBL1870914
6.31	IC50	490	nM	CHEMBL1316867
6.25	IC50	558	nM	CHEMBL1870914
6.23	IC50	589	nM	CHEMBL1316867
6.20	IC50	635	nM	CHEMBL1525161
6.16	IC50	696	nM	CHEMBL281980
6.12	IC50	757	nM	CHEMBL3191962
6.12	IC50	750	nM	CHEMBL1402456
6.12	IC50	750	nM	CHEMBL1891588
6.10	IC50	788	nM	CHEMBL1421255
6.10	IC50	797	nM	CHEMBL1506796
6.07	IC50	857	nM	CHEMBL1542328
6.07	IC50	854	nM	CHEMBL1879394
6.06	IC50	863	nM	CHEMBL1967857
6.05	IC50	890	nM	CHEMBL1891206
6.05	IC50	896	nM	CHEMBL1586985
6.04	IC50	920	nM	CHEMBL1871228
6.04	IC50	910	nM	CHEMBL1884442
6.03	IC50	938	nM	CHEMBL1475128
6.02	IC50	955	nM	CHEMBL1418096
6.02	IC50	960	nM	CHEMBL1869393
6.01	IC50	987	nM	CHEMBL1871228
6.01	IC50	985	nM	CHEMBL1869875
6.00	IC50	1010	nM	CHEMBL3195102
6.00	IC50	1000	nM	CHEMBL1302779
6.00	IC50	1000	nM	CHEMBL1319405
5.99	IC50	1020	nM	CHEMBL1449923
5.97	IC50	1060	nM	CHEMBL1889650
5.96	IC50	1100	nM	CHEMBL1577231
5.96	IC50	1100	nM	CHEMBL1878061
5.96	IC50	1100	nM	CHEMBL1884495
5.94	IC50	1140	nM	CHEMBL595840
5.94	IC50	1160	nM	CHEMBL1869393
5.92	IC50	1210	nM	CHEMBL1891206
5.92	IC50	1200	nM	CHEMBL1877777
5.91	IC50	1220	nM	CHEMBL1988780
5.91	IC50	1230	nM	CHEMBL1302779
5.89	IC50	1300	nM	CHEMBL1885269
5.88	IC50	1310	nM	CHEMBL1773702
5.88	IC50	1310	nM	CHEMBL1412015
5.87	IC50	1360	nM	CHEMBL1417815
5.87	IC50	1350	nM	CHEMBL1577231
5.87	IC50	1360	nM	CHEMBL1319405
5.87	IC50	1350	nM	CHEMBL1582654
5.86	IC50	1390	nM	CHEMBL1877777
5.85	IC50	1400	nM	CHEMBL1866613
5.85	IC50	1400	nM	CHEMBL1890591
5.85	IC50	1400	nM	CHEMBL1901952
5.84	IC50	1460	nM	CHEMBL1521051

PubChem BioAssay actives

2 with measured affinity, of 9 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-amino-4-[[4-[4-[(2-amino-6-sulfonaphthalen-1-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]naphthalene-2,7-disulfonic acid	1859347: Inhibition of His-tagged human SENP7 expressed in Escherichia coli (DE3) using YFP-SUMO-ECFP as substrate incubated for 15 mins by Coomassie staining based SDS-PAGE analysis	ic50	2.7000	uM
[3-[[2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[2-(4-hydroxy-3-nitrophenyl)acetyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]acetyl]amino]-2-oxopropyl] anthracene-9-carboxylate	1799555: Fluorogenic Assay from Article 10.1016/j.chembiol.2011.05.008: “Development of small molecule inhibitors and probes of human SUMO deconjugating proteases.”	ic50	4.3000	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects expression, affects methylation, decreases expression	5
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	4
perfluorooctane sulfonic acid	decreases expression	2
entinostat	decreases expression, affects cotreatment	2
Arsenic	decreases expression, affects cotreatment, increases abundance	2
Valproic Acid	decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Acetaminophen	decreases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Clorgyline	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects expression	1
Folic Acid	decreases expression	1
Manganese	decreases expression, increases abundance, affects cotreatment	1
Methyl Methanesulfonate	increases expression	1

ChEMBL screening assays

6 unique, capped per target: 3 functional, 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1738495	Functional	PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS for inhibitors of Sentrin-specific protease 7 (SENP7) using a Luminescent assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID434973, AID434986]	PubChem BioAssay data set
CHEMBL5114417	Binding	Inhibition of His-tagged human SENP7 expressed in Escherichia coli (DE3) using YFP-SUMO-ECFP as substrate incubated for 15 mins by Coomassie staining based SDS-PAGE analysis	Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases. — Eur J Med Chem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1C7	Ubigene SK-BR-3 SENP7 KO	Cancer cell line	Female
CVCL_E2JS	HAP1 SENP7 (-) 2	Cancer cell line	Male
CVCL_E2JT	HAP1 SENP7 (-) 3	Cancer cell line	Male
CVCL_XS56	HAP1 SENP7 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

4 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05393375	Not specified	COMPLETED	Arthrogryposis Multiplex Congenita in Pediatric Age: Correlation Between MUScular MRI and Functional Evaluation
NCT05673265	Not specified	UNKNOWN	Pediatric and Adult Registry for Patients With ARThrogryposis
NCT06130592	Not specified	UNKNOWN	Technical Feasibility Study of Ultrasound Muscle Imaging in Antenatal Ultrasound
NCT07360574	Not specified	NOT_YET_RECRUITING	Piezo2-related Arthrogryposis & physiopathOLOgy 3